Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Bionano Genomics, Inc. is a life sciences technology company focused on genome analysis solutions that enable the detection of large-scale structural variants in DNA. The company operates primarily in the genomics, cytogenetics, and molecular diagnostics research industries, serving academic researchers, clinical research laboratories, and translational research institutions. Its core offering is optical genome mapping (OGM), a technology designed to complement or replace traditional cytogenetic methods such as karyotyping, FISH, and chromosomal microarrays in research and clinical research settings.
The company’s primary revenue drivers include sales of its Saphyr System, associated consumables and reagents, and software subscriptions. Bionano is positioned as a specialist in high-resolution detection of structural variants and copy number variations, which are difficult to characterize with short-read sequencing alone. Founded in 2003, the company evolved from an early-stage genome imaging innovator into a publicly traded company following its 2018 initial public offering, subsequently expanding its portfolio through targeted acquisitions and software development.
Business Operations
Bionano Genomics generates revenue through instrument placements, consumables, and software licenses across its core business segments: Genome Analysis Systems, Consumables and Reagents, and Software and Informatics. The Saphyr System is the company’s flagship platform, supported by Bionano Prep kits and labeling reagents that produce recurring consumables revenue. Software products, including Bionano Access and Bionano Solve, support data analysis, visualization, and interpretation.
Operations are primarily research-use-only, with customers located in both domestic and international markets. The company strengthened its informatics capabilities through its acquisition of BioDiscovery, which added the NxClinical software platform used in cytogenetic analysis. Bionano also owns Lineagen, a subsidiary focused on genetic testing services, though its strategic importance has shifted over time. Distribution outside the United States is conducted through a mix of direct sales and third-party distributors.
Strategic Position & Investments
Bionano’s strategy centers on driving broader adoption of optical genome mapping as a standard tool in cytogenetics and cancer research workflows. Growth initiatives include expanding clinical research applications in oncology, hematological malignancies, and rare disease research, as well as increasing the installed base of Saphyr systems to drive consumables pull-through.
The company has pursued inorganic growth to strengthen its software and clinical interpretation capabilities, most notably through the acquisitions of Lineagen and BioDiscovery. Bionano is also investing in next-generation chemistry, higher-throughput workflows, and integrated analysis solutions that combine structural variant detection with complementary genomic data. Its strategic positioning emphasizes differentiation from sequencing-centric platforms by focusing on large, complex genomic alterations.
Geographic Footprint
Bionano Genomics is headquartered in North America (San Diego, California) and maintains a commercial and operational presence across Europe and the Asia-Pacific region. The United States represents its largest market, supported by direct sales, customer support, and research collaborations.
Internationally, the company operates through a combination of regional offices and distributor networks, with established market presence in Western Europe, East Asia, and Australia. Bionano’s global footprint supports academic research institutions, clinical research laboratories, and consortium-based genomic studies, contributing to its influence in international cytogenetics research initiatives.
Leadership & Governance
Bionano Genomics was founded by scientists and technologists with expertise in genome imaging; Han Cao, one of the company’s founders, remains involved in scientific leadership. The current executive team emphasizes technological innovation, commercial execution, and integration of hardware and software solutions to advance genome analysis.
Key executives include:
- Erik Holmlin – President and Chief Executive Officer
- David Bendel – Chief Financial Officer
- Han Cao – Chief Scientific Officer
- Ting Wu – Chief Technology Officer (Data inconclusive based on available public sources regarding current title continuity)
The leadership philosophy centers on establishing optical genome mapping as a core analytical modality in cytogenetics, with a strategic vision focused on long-term platform adoption, recurring revenue growth, and continued investment in differentiated genomic technologies.